Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

The association between multiple sclerosis and a diet focusing on fresh produce, fish, and olive oil is particularly strong ...

Multiple sclerosis (MS) is a chronic autoimmune disease characterized by the disruption of nerve signals and various ...

Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.

Sanofi’s PERSEUS phase 3 study of tolebrutinib in primary progressive multiple sclerosis fails to meet primary endpoint: Paris Tuesday, December 16, 2025, 11:00 Hrs [IST] Sanofi ...

Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...

As neurological conditions expose the limits of traditional clinical endpoints, Europe’s regulators are being pushed to ...

Sanofi drug faces FDA delay following a failed late-stage trial for multiple sclerosis, with regulatory guidance expected by Q1 2024.

Sanofi shares slide after FDA delays review of its MS drug tolebrutinib and a late-stage trial fails to meet its main goal.

Elsa Mendoza recalls Fernando as a newborn, learning how to throw tennis balls, and his response to learning she has multiple ...

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...